Posted by Michael Wonder on 08 Jun 2024
Moderna files FDA application for the JN.1 targeting COVID-19 vaccine
7 June 2024 - Manufacturing is underway and doses of Moderna's Spikevax 2024-2025 formula will be ready to ship as early as August, pending regulatory approval.
Moderna today announced that it has submitted an application to the US FDA for review of its Spikevax 2024-2025 formula, targeting the SARS-CoV-2 variant JN.1.
